Citation

Boukhris T. BJOG 2018; 125(9): 1085.

Affiliation

Université de Montréal, Faculty of Pharmacy, 3175, Côte Sainte-Catherine, Montreal, H3T 1C5, Canada.

Copyright

(Copyright © 2018, John Wiley and Sons)

DOI

10.1111/1471-0528.15118

PMID

29316105

Abstract

Antidepressants (ADs) are among the most frequently used medications in pregnancy. ADs can cross the placental barrier (Rampono et al. Pharmacopsychiatry 2009;42(3):95-100, Loughhead et al. Biol Psychiatry 2006;59(3):287-90), resulting in a dysfunction of the serotonergic and norepinephrine systems, which could cause inattention or hyperactivity-impulsivity behaviors as exhibited in ADHD. Several epidemiological studies have investigated the potential link between AD exposure during pregnancy and the risk of attention deficit disorder with/without hyperactivity (ADHD) in children. However, findings have been conflicting. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

Language: en